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Abstract
Pain control is one of the most challenging aspects in the management of chronic pancreatitis. Total
pancreatectomy can successfully relieve the intractable abdominal pain in these patients but will inevi-
tably result in insulin-dependent diabetes. Islet autotransplantation aims to preserve, as far as possible,
the insulin secretory function of the islet cell mass thereby reducing (or even removing) the requirement
for exogenous insulin administration after a total pancreactomy. Despite the relatively small number of
centres able to perform these procedures, there are important technical variations in the details of their
approaches. The aim of this review is to provide details of the current surgical practice for total
pancreatectomy combined with islet autotransplantation, and outline the potential advantages and
disadvantages of the variations adopted in each centre.
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Introduction
Chronic pancreatitis is a condition associated with irreversible
morphological and functional abnormalities secondary to a pro-
longed pancreatic inflammation and fibrosis.1 Steatorrhoea, mal-
absorption, diabetes and abdominal pain of varying degree are the
key clinical features. While malabsorption as a result of steator-
rhoea can be managed with oral pancreatic enzyme supplements
and diabetes with insulin, pain management is at best challenging
and not infrequently intractable. The severity of the pain experi-
enced does not always correlate with the apparent extent of the
morphological changes demonstrated by radiological studies and
this frequently complicates the clinical management. Fortunately
the majority of patients can be managed medically within a mul-
tidisciplinary setting but a proportion of patients may experience
disabling pain that severely affects their quality of life and renders
them chronically dependent on opiates.2
Treatment options are limited but include extensive surgery in
an attempt to remove or dramatically reduce symptoms, less
invasive endoscopic procedures which aim to alleviate chronic
pain and medical management which encompasses analgesia and
regional blocks (with almost inevitable symptom recurrence).
Total pancreatectomy, although a radical approach, is occasion-
ally the only treatment option that can provide complete relief
in these patients.3 The indications for the operation include
patients with small duct disease without focal abnormalities or
those in whom an endoscopic drainage procedure or previous
resectional surgery have failed to relieve pain.4,5 Total pancreate-
ctomy is technically challenging and has traditionally been
associated with high morbidity and mortality rates6 but the
development of specialist centres has improved the operative
and peri-operative management resulting in outcomes com-
parable to those of a pylorus-preserving pancreactico-
duodenectomy.7–9 The benefit of pain relief must nevertheless be
considered in the context of the inevitable consequences of the
procedure. These include exocrine insufficiency and insulin-
dependent diabetes, although it is important to remember that
the vast majority of patients will already require pancreatic
supplements and that without treatment 50–60% of patients
with chronic pancreatitis will eventually require insulin. Autolo-
gous islet transplantation when employed after total pancreate-
ctomy may prevent the onset of diabetes and even when some
exogenous insulin is required, because the infused islets almost
always results in the long-term production of C-peptide and
insulin, diabetic control is simplified.10,11
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Patient selection and initial assessment
Patients with chronic pancreatitis are generally referred for total
pancreatectomy after other treatments have failed to adequately
control their symptoms. The severity of the pain that patients
experience frequently does not correlate with the gross morpho-
logical changes in the gland and the diagnosis of chronic pancre-
atitis is often reached by considering the combination of clinical
symptoms,metabolic features and radiological and/or endoscopic
results. Most of the patients with chronic pancreatitis that are
referred for surgical assessment have already had a number of
investigations over long periods. These generally include meta-
bolic studies for pancreatic endocrine and exocrine functions,
computed tomography, magnetic resonance imaging, laparos-
copy, endoscopic retrograde cholangiopancreatogrphy and, in
some centres, endoscopic ultrasound.
The Leicester, Minnesota, Cincinnati and Alabama groups have
all adopted a multidisciplinary approach in the patient selection
process for total pancreatectomy with/without islet autotrans-
plantation.3,5,12,13 Table 1 shows the basic demographics of the
patients who underwent pancreatectomy and islet autotransplan-
tation in these centres. The aetiology of chronic pancreatitis in
these patients was quite similar amongst the centres except for the
Cincinnati series which had a much lower proportion of chronic
pancreatitis secondary to alcohol.
The islet autotransplantation programme in Leicester was
established in 1994 and after referral all patients are formally
assessed by a multidisciplinary team. Patients undergo laboratory
testing of their exocrine and endocrine functions by means of a
glucose tolerance test, serum HbA1c level, oral butterfat test and
faecal elastase 1 estimations. The multi-disciplinary team consists
of a pancreatic surgeon, a diabetologist, a gastroenterologist, a
pain specialist, an anaesthetist and a medical psychologist. Any
member of the multi-dsiciplinary team can veto the decision to
proceed with surgery if it is felt inappropriate. A clinical nurse
specialist provides these patients with information and counsel-
ling regarding the procedure as well as introducing the potential
candidates to two patients who have had a total pancreatectomy
and islet autotransplantation (one who underwent the procedure
within 12 months and the other more than 12 months ago) to
facilitate their understanding of immediate and long-term post-
operative recovery and gain realistic expectations. A further
meeting is then scheduled in the clinic at least a month after the
assessment to discuss consent with the patients (and their family if
appropriate).
In Leicester, islet isolations are routinely attempted in patients
with normal glucose tolerance tests who undergo total pancreate-
ctomy for intractable pain, regardless of the severity of morpho-
logical changes to the pancreas. Patients with abnormal glucose
tolerance tests may be considered for an islet autotransplant after
discussion in the outpatients (with the aim of producing some
background insulin production). Performing the procedure in
these patients is based on the understanding that any beta cell
mass, and the consequent insulin production, will result in
improved diabetic control and reduce the long-term complication
rate and a similar approach is adopted at the University of Min-
nesota.5 Patients who already require insulin are not considered
for islet autotransplantation but total pancreatectomy will still be
considered for pain relief. For patients where splenic preservation
is not considered to be an option and in centres where splenec-
tomy is performed routinely with total pancreatectomy, pre-
operative vaccinations for Haemophilus influenza, Pneumococcus
and Meningococcus are given.
The surgical approach to total pancreatectomy
Total pancreatectomy aims to completely remove the diseased
pancreas, abolishing rather than reducing the chronic pain. The
advantage over partial pancreatic resection or a surgical drainage
procedure is that there is no potential for pancreatic duct leakage
and the diseased gland is completely excised. However, it is a
lengthy and complex procedure particularly if patients have had
previous pancreatic surgery or severe inflammation, particularly
pseudocyst formation.
There are similarities and differences in the surgical
approach to total pancreatectomy among the three largest islet
Table 1 Comparison of demographics and aetiology of patients in different centres
Demographics Leicester9 Cincinnati12 Minneapolis10,17,19 Alabama3
Age (mean, years) 43 38 35 44
Gender (M : F ratio) 1 : 1.1 1 : 2 1 : 2.4 1 : 0.9
Body mass index (mean, kg/m2) 22 26 N/A 22
Median duration of symptoms (months) 65 (25–287) N/A 72 (12–240) N/A
Aetiology (% patients)
Alcohol 36% 4% 20% 35%
Idiopathic 48% 87% 50% 31%
Biliary 10% Not specified 12% 4%
Others 6% 9% 18% 30%
N/A, Data not available.
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autotransplantation series worldwide9,10,12,14–16 and these are
shown in Table 2.
Some aspects of the operation are common among the centres.
Generally, the blood supply of the pancreas is preserved for as long
as possible to minimize the warm ischaemic time. This can be
achieved by preserving the venous drainage as well as the arterial
supply of the pancreas via the splenic vessels until the point of
pancreas removal. Meticulous dissection and attention to haemo-
stasis is crucial as the risk of bleeding is increased because full
heparinization is carried out prior to islet infusion and the islet
infusion induces transient portal hypertension.
Preservation of the whole duodenum was originally advocated
in pancreatic resections for benign diseases to retain the physi-
ological bile secretion but this approach is associated with an
increased complication rate as the vascular supply to the
retained duodenum is compromised secondary to interruption
of the pancreaticoduodenal arcade.10,17 Nevertheless total pancre-
atectomy with partial duodenectomy is still preferred by some
centres.18,19 It is theoretically also preferable to keep the pancre-
atic capsule intact and avoid transection of the pancreas intra-
operatively (Fig. 1) to facilitate the collagenase digestion and to
minimize the period of warm ischaemia. However in some
centres this is felt to prolong the procedure (and the warm
ischaemia time) unduly and thus negate the potential advantage
that this offers and consequently this practice has not been rou-
tinely adopted in all centres.15
During the early development of the procedure it was believed
that splenectomy could not be avoided but with the recognition
of the important role that the spleen plays in maintaining
immunological functions, in the mid 1990s a number of groups
attempted splenic preservation and demonstrated that not only
was it possible but it could be achieved in the majority of
patients. It has subsequently been shown that in the absence of
previous pseudocyst formation that has involved the splenic
vessels then they can be preserved. If both vessels cannot be pre-
served, the splenic vein may be retained but the artery must not
be left in isolation. Even in patients where this is not possible the
spleen is usually viable when the short gastric vessels are not
involved in the fibrotic process. Our experience in Leicester is
that even with the temporary rise in portal pressure from the
subsequent islet infusion this can safely be achieved in almost all
patients.9,14 Other centres still have a lower threshold for sple-
nectomy as a result of concerns over the risks of variceal forma-
tion in the short gastric veins with the potential for late
intestinal bleeding and painful splenomegaly, although this has
not been our experience.5
Table 2 Comparison of the surgical approaches adopted by the three largest published series of total pancreatectomy and islet
autotransplantation
Leicester series (55 to date) Minnesota series (>200 to date) Cincinnati series (>130 to date)
Pancreatic
resection and
duodenectomy
Total with partial duodenectomy
Pylorus preserving and preserving
4th part of duodenum
Pancreas resected as a whole
Earlier series were near total with
preservation of entire duodenum
Past 15 years, partial duodenectomy,
preserving pylorus and 4th part of
duodenum
Pancreas resected as a whole
For near-total pancreatectomy, a small
rim (<5%) of pancreas left along with
the C-loop of the duodenum, with
the common bile duct and
pancreaticoduodenal artery and entire
duodenum left intact
For total pancreatectomy, partial
duodenum with or without preserving
the pylorus
Pancreas divided at the level of superior
mesenteric artery with the distal portion
sent for islet isolation while dissection
around the head of pancreas continues
Spleen Spleen preserving, supplied by
the short gastric vessels
Splenectomy performed unless it
retains an absolutely normal
appearance after hilar ligation
Routine splenectomy
Reconstruction End-to-end duodeno-duodenostomy or
end-to-side duodenojejunostomy
Choledochoduodenostomy
End-to-end duodeno-duodenostomy
or end-to-side duodenojejunostomy
Choledochoduodenostomy
Not required in near-total pancreatectomy.
Side-to-side gastrojejunostomy or
end-to-side duodenojejunostomy
End-to-side hepaticojejunostomy
Figure 1 Pancreas resection with capsule intact and along with part
of the duodenum
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Islet isolation and preparation
In the United Kingdom, islet isolation must be performed in a the
Human Tissue Authority accredited laboratory and a Food and
Drug Administration approved laboratory in the United States.
After excision of the pancreas, the pancreatic duct is cannulated
and the organ distended with collagenase and digested according
to the modified automated method widely described.13,20–22
Islet purification is not a compulsory step of islet processing
and transplantation. The purpose of islet purification is to reduce
the volume of infusion in order to avoid an excessive rise in portal
pressure, however, this must be balanced against the risk of
wastage of islet cells.23 Islet purity is determined subjectively by a
visual assessment using two 100-ml sampling strips. A comparison
is made comparing the relative quantity of dithizone-stained islets
(red) to unstained acinar tissue (yellow).24 Islet yields are
expressed as international islet equivalents (IEQ).25,26
In Leicester, we prefer to transplant whole pancreas digest if
possible as our earlier experience clearly demonstrated that puri-
fication compromised the number of islets recovered.20 At least
40% of islet cell mass will be lost during purification and this is
generally less than the amount that would need to be discarded if
unpurified digest was employed. At the University of Minnesota,
islet purification is preferred except in patients where the tissue
volume is so low that there would be no advantage.5
Before transplantation, islet preparations are suspended in a
50 : 50 solution of 20% human serum albumin (Zenalb 20, Bio-
Products, Laboratories, Elstree, UK) and M199 transplant media
(Cambrex, Woking, UK). We infuse the islets into the left lobe of
the liver via the portal vein (accessed by way of the middle colic or
recannalated umbilical vein) and 5000 units of intravenous
heparin is administered routinely (immediately prior to islet infu-
sion) to prevent intra-portal thromboses.
Route of islet transplantation/portal vein
access
The most common site for islet autotransplantation is the liver via
intraportal infusion. Other sites had been explored both in animal
models and in humans with the hope of avoiding the associated
risks of portal hypertension, venous thrombosis and infarction.
Intrasplenic islet transplantation had successfully led to insulin
independence in some animal models but was associated with a
high morbidity in humans as a result of splenic infarctions and
venous thromboses.21,27–30 The portal system can be accessed via a
number of different routes and we routinely infused the islet into
the left lobe of the liver alone to allow for a salvage procedure in
the event of serious complications.
Umbilical vein
This method of portal venous access has been used for many years
for total parenteral nutrition in neonates (where the umbilical
vein is patent) and occasionally in adults with intractable vascular
access problems. The obliterated umbilical vein (the ligamentum
of teres hepatis) can be easily identified and recanalized with a
Bakes dilator after transection of the falciform ligament, giving
access to the left portal vein for the infusion of islet isolates
(Fig. 2). To date, we have used this technique in 16 patients with
ultrasound evidence that the vast majority of islets are successfully
transplanted into the left lobe of the liver.31 The vein can also be
exteriorized by pulling the ligamentum teres through a 10-mm
laparoscopic port in the epigastrium and then after being sutured
to the skin and covered with a sterile dressing can be accessed for
up to 5 days post-operatively for the measurement of portal pres-
sure or theoretically for the infusion of pharmacologically active
agents. We have used this technique to monitor portal pressures
and we have experienced no intra-operative or post-operative
complications related to this.32 In addition, the umbilical vein can
also be approached above the umbilicus under local anaesthetic
and with the demonstrated safety of this access route would
appear to be an ideal route for allotransplantation and has the
additional advantage that the exteriorised vein would facilitate
repeated transplants if they were required.
Middle colic vein or mesenteric vein
Prior to developing a technique for use of the umbilical vein we
used to infuse islets into the left lobe of the liver via the middle
colic vein. The middle colic vein was identified intra-operatively
and cannulated within the transverse mesocolon in a manner
similar to other mesenteric vein approach described in the litera-
ture.33 Although this can be accessed easily through a minilaparo-
tomy with a Rocky Davies incision, it requires the patient to
remain anaesthetized during the islet administration and repeated
infusions are not feasible as the vein cannot be exteriorized.
Omental vein
The Minnesota group described the omental vein approach in
which an omental tongue around a venous tributary can be
Figure 2 Infusion of islet via a catheter inserted into the recanalized
umbilical vein
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fashioned into a pedicle that can then be exteriorized through a
transverse lateral abdominal wall incision.34 This approach confers
similar advantages to theumbilical vein approach as it allowsportal
pressure measurements. In addition should the primary total pan-
createctomy and gastrointestinal reconstruction be completed sig-
nificantly before the islet isolation process is completed, the patient
can be woken up and the islet infusion performed in the recovery
area, thereby reducing the overall duration of anaesthesia.
Transhepatic
Transhepatic islet infusion can be performed under local anaes-
thesia (generally with sedation) under imaging guidance.35 This is
an advantage in the setting of islet allotransplantation and the
approach has been adopted by the Edmonton group and is
included in their protocol.36 Unfortunately this method of
intraportal islet infusion has been associated with frequent minor
and occasionally major complications (similar to those experi-
enced with liver biopsy) and these include bleeding, damage to
neighbouring structures and thromboses.37,38
Results of islet autotransplantation
The largest series of islet autotransplantation to date are from
Minneapolis, Leicester, Cincinnati and Alabama. The outcomes
traditionally used to measure the success of total pancreatectomy
with islet autotransplantation include metabolic function (insulin
requirement), pain control (narcotics requirement), quality of life
and the morbidity and mortality associated with the surgery.
Metabolic function
Table 3 compares the results of metabolic function of the four
largest series. Islet equivalents serve as an indirect measurement of
the b-cell mass infused. The number of islet equivalents isolated is
influenced by a number of factors including the extent of fibrosis
of the pancreas, previous pancreatic resection and previous sur-
gical drainage procedures. The wide range and standard devia-
tions of islet equivalents reported in the literature reflects the
variability in islet isolation experienced by all centres.
The length of time between excision of the pancreas and islet
infusion is consistent (between 3 and 4 h) across the series. This is
largely as a result of the fact that total pancreatectomy, islet isola-
tion and islet transplantation were carried out in the same site.
The pancreata are subjected to a minimal period of cold ischaemia
in autotransplantation as opposed to those in allotransplantation
where the cold ischaemia time can be highly variable and may
have a significant effect on the quantity and quality of the islets
isolated.39,40 Islet purification does not improve insulin indepen-
dence in islet autotransplantation.20
Insulin independence is achieved in up to 40% of patients
after total pancreatectomy with islet autotransplantation41 and
C-peptide production can be demonstrated in all patients.
C-peptide levels also increase after an oral glucose tolerance test
and demonstrate little deterioration with time after transplanta-
tion.20 Evidence from islet allotransplantation has demonstrated
that stimulated C-peptide levels are an early marker of islet
allograft function and recipients who are C-peptide positive (even
though they may be insulin dependent) are metabolically more
stable.42,43 The same is true for islet autotransplantation and
C-peptide production is likely to confer long-term protection
in a similar fashion to insulin-treated diabetes where preservation
of some insulin production improves long-termglycaemic control.
Higher islet equivalents per kilogram of body weight have been
shown to correlate with insulin independence15,41 although the
correlation is not as straightforward as long-term insulin inde-
pendence had been demonstrated in patients who received as
little as 882 IEQs/kg body weight.44 In addition, a significant
proportion of patients who are not insulin independent after islet
autotransplantation only require very small amounts of exogenous
insulin to achieve excellent control of their blood sugar.3,12,20,41
Islet autotransplantation and allotransplantation contrast in
many aspects. Islet allografts can be obtained from single or mul-
tiple donor(s) and be given as repeated infusions. Immunosup-
pression is essential to prevent allograft rejection despite the
undesirable diabetogenic side-effect of even the latest steroid free
regimens. Finally donor characteristics and duration of cold
ischaemia are extremely variable in allotransplantation (princi-
pally due to the longer cold ischaemia times with islet allografts).
These differences give rise to the discrepancy in the results
between islet autotransplantation and islet allotransplantation.
Despite the greater number of islet equivalents (per kilogram of
body weight) that are transplantated during islet allografting
(from single or multiple donors), insulin independence after islet
allotransplantation is poorly sustained when compared with islet
autotransplantation. Only 71% of recipients of islet allografts
who achieved insulin independence retained this status at 1 year
and this figure reduces to 52% at 2 year whereas 74% of islet
autotransplantation patients who were insulin dependent
remained so at 2 years post transplant.41,45
Pain control and quality of life
One of the goals of total pancreatectomy is to improve quality of
life by alleviating the intractable abdominal pain which renders
these patients dependent on opioid analgesics. All leading centres
for total pancreatectomy with islet autotransplantation have dem-
onstrated a significant improvement in pain score after surgery
and a significant reduction in the use of opiate analgesia (Table 4).
The Cincinnati series also reported a significant improvement in
quality of life using a validated standard assessment questionnaire
(SF-36).15 In Leicester, a questionnaire was sent out to patients to
obtain their assessment on the success of total pancreatectomy in
terms of pain relief and none of the patients felt that they had not
benefited from the surgery.9
Morbidity and mortality surrounding surgery
Total pancreatectomy with islet autotransplantation is only
carried out in highly specialized centres with both surgical
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expertise and accredited scientific laboratory facilities. As a con-
sequence, the surgical results after total pancreatectomy in these
units are excellent with peri-operative mortality rates of around
2%. Table 5 summarizes the surgical outcomes of total pancreate-
ctomy with islet autotransplantation in the leading centres.
Discussion
Total pancreatectomy, although a radical procedure and a signifi-
cant surgical challenge, may be the only treatment option for a
subgroup of patients with chronic pancreatitis. These patients
suffer from relentless abdominal pain which frequently produces
an appalling quality of life despite maximal medical management.
The operation can successfully remove the pain that these patients
experience and this is evident by the significant reduction in
analgesia requirement reported. However, a small proportion of
patients remain opioid dependent. It is important to note that
patients with chronic pancreatitis often have other co-morbidities
which continue to cause pain symptoms necessitating opioid anal-
gesia. In addition, prolonged opioid dependence in some of the
patients may have led to addiction accounting for their ongoing
requirement post pancreatectomy.
Without preservation of the islet cell mass exogenous insulin
therapy is required post-operatively to prevent the complications
of diabetes but may require intensive regimens and subject these
patients to the risk of serious hypoglycaemia.5 In addition, reten-
tion (or restoration) of some insulin production considerably
simplifies the management of diabetes and reduces the long-term
complication rate.38
Autotransplantation of islets recovered from the resected pan-
creas will preserve a proportion of the beta cell mass and result in
some endogenous insulin production. Even although insulin
independence cannot not be achieved in a significant proportion
of patients after islet autotransplantation, the control of their
diabetes is superior to those patients who have a total pancreate-
ctomy where islet transplantion is not possible.9
Thefirst total pancreatectomywith islet autotransplantationwas
carried out in 1977 at the University of Minnesota, Minneapolis.13
Since then, there have been over 300 total or near-total pancreate-
ctomies with islet autotransplantation performed worldwide, with
promising results in terms of insulin independence and long-term
islet graft function.5,15 In addition, the sustained C-peptide secre-
tionmay have a protective effect against some undesirable diabetic
complications.20 The three largest series of islet autotransplanta-
tion are from Minneapolis and Cincinnati (United States of
America) and Leicester (United Kingdom). All series describe
similar populations with comparable demographics and the
aetiology of their chronic pancreatitis. The success of islet
autotransplantation compares favourably with that of islet allo-
transplantation for patients with insulin-dependent diabetes
despite the advances after the widespread application of the
Edmonton’s protocol, and the long-term results are considerably
better.46–49 The differences are almost certainly explained byTa
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allograft rejection and the diabetogenic effects of even the steroid-
free immunosuppressive regimens required in patients receiving
allotransplants.
There is considerable evidence for a direct correlation between
islet yield and insulin independence,50 and in patients who have
exhausted all non-surgical options early referral may facilitate
assessment and a decision about suitability for treatment. It is
likely that treatment at an earlier stage would improve the
outcome of an islet autotransplantation, particularly if it could
be performed prior to the development of significant endocrine
deficiency associated with the disease progression. Arguably, in
patients with severe abdominal pain secondary to small duct
disease and in those where endoscopic or percutaneous proce-
dures have been unsuccessful, total pancreatectomy and islet
autotransplantation should be considered the first and definitive
surgical treatment. This could significantly reduce the operative
risks as a result of the dense adhesions and fibrosis that are often
encountered in patients who had previous surgical procedure(s).
In addition, by maximizing the islet yield it increases the potential
for insulin independence and improves the patient’s quality
of life at an earlier stage. Efforts directed towards the education of
patients, general practitioners and gastroenterologist are essential
to facilitate this early referral of patients with chronic pancreatitis
for assessment in units that can offer islet autotransplantation.
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